BloodPressureHeartMeds.Net

U.N. meeting on NCDs concludes with pledges to fight chronic diseases

August 12, 2017

"Selective inhibition of HDAC6 by ACY-1215 targets a key protein degradation pathway known to be upregulated in certain cancers, including multiple myeloma. ACY-1215 is thus designed to specifically target cancer cells to achieve disease response accompanied by a potentially more favorable side effect profile compared to currently available HDAC drugs, which can cause dysregulation of normal cells due to comparative lack of selectivity," commented Sagar Lonial, MD, Professor and Vice Chair of Clinical Affairs in the Department of Hematology and Medical Oncology at the Winship Cancer Institute of Emory University and lead investigator in the clinical trial. "This trial is the first clinical step towards development of optimized HDAC6 inhibitor treatment regimens for multiple myeloma, including maximally effective combination drug therapies."

The Phase 1a and 1b portions of the trial will enroll patients with relapsed or relapsed/refractory multiple myeloma in a 21-day treatment cycle to determine the maximum tolerated dose of ACY-1215 as monotherapy or in combination with bortezomib and dexamethasone, followed by up to five additional sequential cycles of treatment. The Phase 2a portion is designed to determine the objective response rate to ACY-1215 in combination with bortezomib and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma over up to six 21-day cycles. The trial is being conducted in several major cancer centers across the United States, including the Massachusetts General Hospital Cancer Center, the University of Wisconsin Carbone Cancer Center, the Winship Cancer Institute of Emory University, and others still pending initiation.

Source Acetylon Pharmaceuticals, Inc.